… Rationale: Environmental poisons may cause or contribute to some cases of Parkinson’s disease (PD). Mitochondrial … amount of damage these toxins may have caused. An accurate test is needed. Hypothesis: We will test the hypothesis that damage to mitochondrial DNA (mtDNA) is greater in people who were exposed to certain …

… developed for disorders of the central nervous system (CNS) to reach therapeutic concentrations in the brain. Therefore, … controlled and targeted delivery of therapies for treating complex CNS disorders such as Parkinson’s disease. Project … necrosis factor (TNF), holds promise as a therapy for PD. However, clinical development is largely hindered by an …

… has generated a number of treatments aimed at treating symptoms of the disease, primarily by addressing dopamine … Similarities and differences between synucleinopathies How to measure long-term benefits of treatments that slow … May 2025. The report notes why it’s so important to fully comprehend the benefits of DMTs:  As of this writing, it is …

… for Parkinson’s disease (PD), the current methods used to identify people suitable for clinical trials are costly, … stimulation (TMS) — to assess neurophysiological markers. Combining these techniques may help to reveal the … measurements to quantify cortical brain activity. The TMS test will be paired with nerve stimulation to measure …

… From left to right: Alexandria, Kate, Duyen and Kylie at Kate's Team … (DIY) staff hit the road — crisscrossing the country to show up for the community-led events that power our mission. From rides and …

… J. Fox Foundation for Parkinson’s Research announced today the launch of its 2006 Community Fast Track research program (CFT ’06). This annual … conducted within a one-year timeframe and a $125,000 budget.  This puts a greater emphasis on speed and outcomes, …